TY - JOUR
T1 - Pentostatin therapy of T-cell lymphomas with cutaneous manifestations
AU - Kurzrock, Razelle
AU - Pilat, Susan
AU - Duvic, Madeleine
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1999/10
Y1 - 1999/10
N2 - Purpose: To determine the side effects of and response to pentostatin in patients with T-cell lymphomas with cutaneous manifestations. Patients and Methods: Pentostatin was administered to 28 patients who had relapsed cutaneous T-cell lymphoma or peripheral T-cell lymphoma with prominent cutaneous disease. The starting dose was between 3.75 to 5.0 mg/m2/d intravenous for 3 days every 3 weeks. Results: Of the 24 patients assessable for response, 17 (71%) achieved a partial remission (46%) or complete remission (25%). The patients had a median number of three (range, one to 12) prior therapies. Of the 86 courses of pentostatin given, 39 were administered at doses of 5.0 mg/m2/d and 30 at doses of 3.75 mg/m2/d. Dose escalation to 6.25 mg/m2/d was possible in only five courses, and toxicity necessitated dose reduction to 2.8 mg/m2/d in 12 courses. The most common side effects were granulocytopenia, nausea, and non-neutropenic fever. Most patients developed significant lowering of CD4 counts. Herpes zoster was seen within 1 year after pentostatin in five patients (19%). Conclusion: Pentostatin is an active agent in heavily pretreated T-cell lymphomas with cutaneous manifestations.
AB - Purpose: To determine the side effects of and response to pentostatin in patients with T-cell lymphomas with cutaneous manifestations. Patients and Methods: Pentostatin was administered to 28 patients who had relapsed cutaneous T-cell lymphoma or peripheral T-cell lymphoma with prominent cutaneous disease. The starting dose was between 3.75 to 5.0 mg/m2/d intravenous for 3 days every 3 weeks. Results: Of the 24 patients assessable for response, 17 (71%) achieved a partial remission (46%) or complete remission (25%). The patients had a median number of three (range, one to 12) prior therapies. Of the 86 courses of pentostatin given, 39 were administered at doses of 5.0 mg/m2/d and 30 at doses of 3.75 mg/m2/d. Dose escalation to 6.25 mg/m2/d was possible in only five courses, and toxicity necessitated dose reduction to 2.8 mg/m2/d in 12 courses. The most common side effects were granulocytopenia, nausea, and non-neutropenic fever. Most patients developed significant lowering of CD4 counts. Herpes zoster was seen within 1 year after pentostatin in five patients (19%). Conclusion: Pentostatin is an active agent in heavily pretreated T-cell lymphomas with cutaneous manifestations.
UR - http://www.scopus.com/inward/record.url?scp=0032888693&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032888693&partnerID=8YFLogxK
U2 - 10.1200/JCO.1999.17.10.3117
DO - 10.1200/JCO.1999.17.10.3117
M3 - Article
C2 - 10506607
AN - SCOPUS:0032888693
SN - 0732-183X
VL - 17
SP - 3117
EP - 3121
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 10
ER -